[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643062":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":51,"collaborators":53,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":10,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Michigan Rogel Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients undergo urine and blood sample collection, provide family history of cancer and have their medical records reviewed throughout the study. Patients also undergo a digital rectal examination, complete a questionnaire and receive results of the PSA blood test and urine biomarker test. Patients with an elevated PSA level above 2.0 ng\u002Fml (age 40-49) or 2.5 ng\u002Fml (age 50-70) or abnormal urine test will be referred for an ultrasound-guided biopsy of the prostate gland.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Non-Interventional Study","Non-interventional study",[9],[20,21],"Non-Interventional Observational Study","Noninterventional (Observational) Study",[23],{"name":24,"affiliation":5,"role":25},"Todd M Morgan, MD","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Cancer AnswerLine","CONTACT","1-800-865-1125","CancerAnswerLine@med.umich.edu",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Ann Arbor","Michigan","48109","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-83.74088,42.27756,{"lat":44,"lon":43},[47,49],{"name":28,"role":29,"phone":48,"phoneExt":10,"email":31},"800-865-1125",{"name":50,"role":25,"phone":10,"phoneExt":10,"email":10},"Todd M. Morgan, MD",{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[54],{"name":55,"class":56},"National Cancer Institute (NCI)","NIH","100643062","targeted-early-detection-program-in-men-at-high-genetic-risk-for-prostate-cancer-100643062",false,"NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer","Inclusion Criteria:\n\n* \\* Age 35-70 years\n\n  * Capable of providing informed consent\n  * Prognosis of \\> 5 years if affected by another cancer\n  * Patients need one to meet at least one of the following high genetic risk categories:\n\n    * Known PCa-related mutations: BRCA 1 and 2, Lynch syndrome, or p53\n    * Carrier of mutation in a suspected PCa-related gene: e.g., ATM, PALB2, CHEK2, RAD51D, ATR, NBN, GEN1, RAD51C, MRE11A, BRIP1, FAM175A, HOXB13\n    * Obligate carriers of the above mutations (e.g. their sisters\u002Fdaughters have known mutations)\n    * Men with any family history of above mutation\n    * Family history of breast, prostate, or ovarian cancer in at least 2 individuals, or in 1 individual diagnosed before age 50\n\nExclusion Criteria:\n\n* \\* Anuria\n\n  * Prior diagnosis or treatment for PCa\n  * Failure to provide informed consent\n  * Life expectancy \\\u003C 5 years","MALE","35 Years","70 Years",{"count":67,"type":68},200,"ESTIMATED","OBSERVATIONAL","This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.",[72],"Prostate Carcinoma","2026-06-08",{"date":75,"type":76},"2026-06-12","ACTUAL",{"date":78,"type":76},"2017-01-01",{"date":80,"type":68},"2030-01",{"name":5,"class":6},1]